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---Antibiotic resistance is rapidly becoming prevalent in both a clinical and a community setting. Alarmingly, it is predicted that failure to address this issue could lead to approximately 10 million deaths per year by 2050. 1 A recent report by the WHO identified tuberculosis (TB) as a global priority for research and development due to its status as the number one global infectious disease killer, causing 1.7 million deaths per year. 2 A further 12 priority pathogens were identified, consisting of Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, Enterococcus faecium, Staphylococcus aureus, Helicobacter pylori, Campylobacter spp, Salmonellae, Neisseria gonorrhoeae, Streptococcus pneumoniae, Haemophilus influenzae and Shigella spp.
Antibiotics such as fluoroquinolones have had great clinical success, however, bacteria have evolved resistance to entire classes of antibiotics. Overexpression of efflux pumps, target-specific mutations, modifications to the bacterial cell wall and the generation of drug-inactivating enzymes can all contribute to bacterial resistance. 3 Consequently, research into chemical series' with the ability to target drug-resistant bacteria are of utmost importance. One method of overcoming site-specific mutation resistance is to target alternative binding sites which are capable of inducing the same phenotypic response.
DNA gyrase and topoisomerase IV are two examples of highly homologous bacterial type IIA topoisomerases which have the ability to break, reorganise and religate DNA strands. 4 Without recourse to these enzymes, bacteria are not able to appropriately manipulate the topology of their DNA, resulting in eventual cellular death. Fluoroquinolones target the DNA binding site of topoisomerases in order to elicit their therapeutic effect, however, recent publications have focused on inhibition at an alternative site (the ATPase sites on GyrB/ParE on DNA gyrase/topoisomerase IV respectively) in order to circumvent resistance mechanisms. In the 60 years since the first GyrB/ParE inhibitor, novobiocin 1 (Figure 1 ), was discovered, many chemical series have been developed through fragment-based screening, high-throughput screening and scaffold hopping. [5] [6] [7] [8] [9] [10] Herein we describe the discovery and structure-activity relationship (SAR) of a novel series of amide-linked pyrimido [4,5-b] indol-8-amine inhibitors of bacterial type II topoisomerase, which were identified using computational analysis of published GyrB inhibitors and an antibacterial library screen. It was observed in many of the previously published crystal structures of GyrB that a flexible loop adjacent to the ATPase site was poorly ordered, and usually omitted from the deposited coordinates (green arrow, Figure  2a) . Due to the absence of the resolved loop in many structures, proposed interactions in this area have been poorly modelled computationally. However, when an X-ray crystal structure in which this loop was resolved (PDB: 3G7E, green) was overlayed with a range of inhibitors, an unexplored vector near Asp106 was revealed (blue arrow). It was postulated that establishing initial SAR along this vector could serve to both probe the computational model and allow elaboration of a novel inhibitor series. Investigation of the SAR in this way could afford improvements to a variety of PK properties, by highlighting a region of the scaffold from which further optimisation could progress. In combination with these structural studies, an in-house compound library screen identified hit compound 2aa (Figure 2b, Table 1 ), where the substituent probing the Asp106 vector is attached via a novel amide linker. This discovery prompted further investigation of the novel amide-linked pyrimido [4,5-b] indol-8-amine scaffold as a means of challenging the SAR in this region.
Utilising the previously reported intermediate 3 11 (Scheme 1) allowed the synthesis of final compounds 2aa-2di to proceed efficiently via a reproducible, reliable route, from which a range of analogues could be generated. Disulfone 3 was identified as an important intermediate, since several points of diversity could be explored from this compound. Substitution with a variety of 3-substituted pyrrolidines yielded compounds 4, with the relative structural configuration established through an observed Nuclear Overhauser effect between the pyrrolidine substituent and the pyrimidine core (Scheme 1).
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Figure 2. a) Proposed vector (blue arrow), from which the inhibitor could be expanded in the side-chain pocket, towards Asp106. Figure generated from overlaying structures of 3G7E, 12 4K4O 10 and 5D7C. 13 The flexible loop of residues, which are omitted in all structures but present in 3G7E, is highlighted in green. The approximate space-fill surface for the majority of published inhibitors is shown in black. b) Hypothesised amide-linked pyrimido [4,5-b] indol-8-amine compounds that could utilise a previously underexplored vector (blue arrow). Both figures generated using Maestro Version 10.6.014. Scheme 1. Use of disulfone 3 to introduce structural diversity. Reagents and conditions: (i) substituted pyrrolidine, K2CO3, EtOH, 45 °C, 50 min, MW, 61 -89% (ii) NaCN, DMF, 100 °C, 16 h, 60 -89% (iii) Raney nickel, H2, EtOH, rt, 16 h, 68-97% (iv) ArCOOH, EDCI, Et3N, DCM, rt, 16 h, 13 -67% (v) HCl (4N in dioxane), MeOH, rt, 16 h, 14 -99%.
Aromatic nucleophilic substitution of 4 with sodium cyanide then afforded key intermediate 5 (Scheme 1), which could be elaborated through nitrile reduction, unmasking primary amines of the form 6. Amide coupling with an appropriate carboxylic acid followed by deprotection yielded amides of the form 2aa-2di ( Table 1) . The carboxylic acids were selected on the basis of their commercial availability and similarity to those previously reported in the literature.
Final compounds 2aa-2di were tested against a panel of antibacterial strains (Table 1) , including gram-positive pathogens (E. faecalis and S. aureus), gram-negative pathogens (E. coli) and mycobacteria (M. smegmatis and M. tuberculosis).
Incorporation of an oxazole moiety at the amide (2ac and 2ad), provided potency against M. smegmatis and M. tuberculosis (Table 1) . Interestingly, a potency increase against gram-positive bacteria and mycobacteria was observed upon N,N-dimethylation of the 3-aminopyrrolidine, consistent with the hypothesised increase in permeability upon removal of the H-bond donating ability of the primary/secondary amine. Encouraged by the improved potency of the oxazole subseries, the SAR was further challenged through subsequent methylation of the oxazole ring. Oxazole methylation tended to increase the potency for a series, however, the position of optimal methylation was variable. Computational methods (See Computational Analysis section, below) were utilised to aid rationalisation of these results. In order to further profile the series, a selection of compounds were tested against a broader panel of grampositive and gram-negative bacteria, and assessment of their in vitro cytotoxicity was undertaken ( Table 2) .
Representative compounds were found to partially retain activity against a broader spectrum of bacteria, with no toxic effects observed in a HepG2 mammalian cytotoxicity assay for the majority of the tested compounds. Importantly, examples from the series were found to be more potent against M. tuberculosis than novobiocin 1. Target engagement was confirmed by testing for the ability of the inhibitor to prevent DNA supercoiling, and through its capacity to inhibit ATP hydrolysis ( Table 3) . Inhibition of human topoisomerase II decatenation highlighted the high bacterial selectivity of the series ( Table 3) .
As a result of the high potency against M. tuberculosis, representative compounds from our novel series were tested against a panel of bacterial strains bearing mechanisms that rendered them resistant to clinically utilised antibiotics. All the resistant strains used were derived from M. tuberculosis H37Rv, and carried resistance mechanisms as outlined in Table 4 .
Gratifyingly, the Redx Pharma series was observed to maintain potency against the tested resistant isolates, highlighting a benefit in the current series compared to the clinically-relevant compounds moxifloxacin, isoniazid, rifampicin and novobiocin. 
COMPUTATIONAL ANALYSIS
Compound 2cf, the result of 2-methylation of the oxazole in 2cd, was found to be 5-fold higher in potency against M. smegmatis compared to the undecorated analogue. Although it was hypothesised that the addition of the methyl group may result in improved permeability through increasing lipophilicity, computational simulations were used to determine if the potency increase was due to a specific interaction. Molecular dynamics calculations were performed using Desmond v2.3 17 (see Experimental section, below) on two hypothetical analogues relating to 2ce and 2cf (9ce and 9cf, Figure 3 ). As the most structurally similar analogue with an X-ray crystal structure (PDB: 4K4O 10 ) utilised a bicyclic amine in the amine pocket, this was kept consistent throughout the simulations to ensure differences in binding could be rationalised primarily through alterations to the heterocycle inhabiting the side-chain pocket.
The simulation showed that the protein-ligand interactions were stable, and key interactions were consistent with those observed in the X-ray crystal structure of similar GyrB inhibitors, providing confidence in the computational method. The most important binding interactions were found to be hydrogen bonds between the three nitrogen atoms on the tricyclic core and Asp73 and its coordinated water. Furthermore, a strong association of the oxazole ring with Arg76 was concordant with a π-cation interaction, consistent with published observations. 10 As the core of the molecule remained unchanged throughout the simulations, focus was placed on how the heterocyclic amide may effect binding. The resulting interaction maps for the oxazole substituents are shown in Figure 4 , with relative interaction probabilities annotated alongside. For example, an interaction probability of 61% related to the interaction being observed to occur during 61% of the simulation. Similar residues were observed to be involved in each compound's binding interactions near the amide substituent, however, the extent of the binding was variable. Arg136 formed a hydrogen bond with the amide carbonyl in both simulations. However, in 9cf, this interaction seemed more stable, with a higher interaction probability (up to 94% compared to up to 49% in 9ce). This improved interaction in 9cf was hypothesised to be a result of the oxazole-methyl group in 9cf causing a steric clash with Arg136 in the active site, discouraging binding (Figure 5a) . Movement of the methyl group to the 2-position of the oxazole could alleviate this clash, decreasing the overall energy of the system, and contributing to an increase the potency of the ligand. Interestingly, an additional potency driving interaction may be picked up by 9cf to Asp106, which resides on the flexible loop commonly omitted from the majority of deposited X-ray crystal structures. The nitrogen atom in the oxazole ring of 9cf may be in a more appropriate orientation to bind via a watermediated interaction to Asp106 (Figure 5b) . The existence of this interaction may reflect the increase in M. smegmatis potency observed between compounds 2ce and 2cf. Furthermore, elaboration along the vector towards Asp106 may provide additional potency-driving interactions to optimise the series.
In summary, utilising computational analysis of previously published crystal structures of GyrB inhibitors in DNA gyrase allowed the development of the current antibacterial series, focussing on improving the activity and spectrum of susceptible bacteria. A combination of expanding into an identified area of the active site, and alteration of permeability through removal of H-bond donors, has successfully yielded antibacterial compounds with potent activity against grampositive bacteria and mycobacteria. Furthermore, the potential of the series has been exemplified through the ability of the compounds to maintain activity against a range of drugresistant M. tuberculosis clinical isolates. Subsequent alterations of the amide-linked heterocycles have demonstrated steric bulk can not only be tolerated in this area of the protein, but additional potency increasing interactions could be designed into the inhibitors through interaction with Asp106, which resides on the flexible loop.
EXPERIMENTAL

Molecular dynamics
Protein structures were prepared using Maestro's Protein Preparation Wizard (PrepWizard), following the procedure outlined by Sastry et al. 18 Unfortunately, the X-ray crystal structure of 4K4O 10 (E. faecalis) was not complete, and the flexible loop of residues that resided near the pyrimidine substituent were omitted, resulting in the use of a complete crystal structure, 3G7E
12 (E. coli), instead. The suitability of the proteins to be interchanged was assessed by determining that 68% of residues within the active site were identical. Of the non-identical residues, mutation was commonly observed to be a result of a small change (e.g VAL to ILE). Each mutated residue was assessed for its contribution to binding, resulting in 95% similarity of the active sites of 4K4O and 3G7E, and could therefore used interchangeably during the computational studies. Furthermore, both sequences were seen to be highly similar to 3ZM7 (M. tuberculosis), allowing comparisons in binding to be drawn from simulations of 3G7E. Each compound was docked using a knowledge-based alignment and the protein-ligand complex was solvated and simulated for 8 ns at a temperature of 300K using the OPLS_2005 force field 19 in Desmond v2.3. 17 The system trajectories were then analysed using Maestro v10. 6 
Supporting information
General remarks
NMR spectra were obtained on a LC Bruker AV500 using a 5 mm QNP probe. Coupling constants are reported in Hz and refer to 3 JH-H interactions unless otherwise stated.
LCMS was carried out on a Waters Alliance ZQ MS using H2O and MeCN mobile phase with pH modification as detailed below. Wavelengths measured were 254 and 210 nm.
LCMS Method (Basic pH)
Column: YMC-Triart C18 50 × 2 mm, 5 µm. -3-yl)carbamate, c) N,N-dimethylpyrrolidin-3 
tert-butyl N-[2-benzylsulfonyl-4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (4c)
Following the general procedure above: a) 700 mg; b) N,N-dimethylpyrrolidin-3-amine, 0.16 mL; c) 241 mg; d) 5 mL; e) 580 mg. 
tert-butyl N-[2-benzylsulfonyl-4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (4d)
Following the general procedure above: a) 1 14 (m, 1H), 1.88 -1.78 (m, 1H), 1.45 (s, 18H) .
General procedure for the synthesis of nitrile substituted intermediates (5a-d)
Following the general procedure below, the data are reported as a) mass of starting material; b) mass of sodium cyanide; c) volume of DMF; d) mass of product obtained.
A solution of sulfone intermediate 4a-d (1.00 -2.86 mmol, 1 eq) and sodium cyanide (2.10 -3.14 mmol, 1.1-2.1 eq) in DMF was heated to 100 °C for 16 h. The reaction mixture was poured into water and extracted with EtOAc. The combined organics were extracted with water, brine, dried (MgSO4), filtered and concentrated in vacuo to give the crude product which was purified by silica gel column chromatography (gradient = 0-100% EtOAc in petroleum ether (bp. 40-60)). The appropriate fractions were combined and concentrated in vacuo to give the corresponding nitrile substituted intermediates 5a-d in good to excellent yield. 
tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-2-cyano-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (5a)
Following the general procedure above: a) tert-butyl N-[2-benzylsulfonyl-4-[3-(tert-
butoxycarbonylamino
tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-2-cyano-6-fluoro-9H-pyrimido[4,5-b]indol-
4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (5b)
Following the general procedure above: a) tert-butyl N-[1-[2-benzylsulfonyl-8-[tert-
tert-butyl N-[4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-2-cyano-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (5d)
Following the general procedure above: a) tert-butyl N- [2-benzylsulfonyl-4-[3-[(tertbutoxycarbonylamino) 
tert-butyl N-[1-[2-(aminomethyl)-8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (6b)
Following the general procedure above: a) tert-butyl N-(4-benzylsulfonyl-2-cyano-6-fluoro-9H-
General procedure synthesis of Boc-protected final compounds (7)
Following the general procedure below, the data are reported as a) mass of starting material; b) mass of acid; c) mass of EDCI; d) volume of DCM; e) volume of NEt3; f) mass of product obtained.
To an ice cold solution of corresponding primary amine 6a-d (0.05 -0.38 mmol, 1 eq), corresponding acid (0.06 -0.48 mmol, 1.3 eq) and EDCI (0.05 -0.49 mmol, 1.3 eq) in DCM was added NEt3 (0.06 -0.53 mmol, 1.4 eq) and the mixture was warmed to RT and stirred for 16 h. The reaction mixture was loaded directly onto a pre-equilibrated silica column and purified by silica gel column chromatography (gradient = 0-100% EtOAc in petroleum ether (bp. 40-60)). The appropriate fractions were combined and concentrated in vacuo to give the corresponding Boc-protected final compound 7. N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-2-[(pyridine-3-carbonylamino) 
tert-butyl
General procedure for Boc deprotection to yield final target compounds (2)
Following the general procedure below, the data are reported as a) mass of starting material; b) volume of MeOH; c) volume of HCl (4M in dioxane); d) mass of product obtained as the HCl salt.
To a solution of corresponding Boc-protected compound 7 (0.006 -0.06 mmol) in MeOH was added HCl (4 M in dioxane) (0.01 -6.30 mmol). The reaction mixture was stirred at RT for 30 min then concentrated in vacuo and azeotroped from MeOH twice to give the corresponding Boc-deprotected final compound 2 in good yield. 4-(3-aminopyrrolidin-1-yl)-6-fluoro-N-methyl-9H-pyrimido[4 
2-(aminomethyl)-
